Mallinckrodt public limited company (MNK)
(Delayed Data from NYSE)
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.14 USD
+0.44 (2.80%)
Updated May 3, 2019 04:02 PM ET
After-Market: $16.14 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Short Playbook on TSLA, HLF and QCOR
by Brian Bolan
A look at a common theme on three battleground stocks where shorts have been crushed.
Should Value Investors Consider Mallinckrodt (MNK) Stock?
by Zacks Equity Research
Is Mallinckrodt (MNK) a great pick from the value investor's perspective right now? Read on to know more.
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright
by Zacks Equity Research
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism.
Mallinckrodt PLC (MNK) Jumps: Stock Rises 15.3%
by Zacks Equity Research
Mallinckrodt PLC (MNK) shares rose more than 15% in the last trading session, amid huge volumes.
Are Options Traders Betting on a Big Move in Mallinckrodt (MNK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.
Lam Research, Mallinckrodt, Texas Instruments, Vishay Intertechnology and Marvell Technology highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Lam Research, Mallinckrodt, Texas Instruments, Vishay Intertechnology and Marvell Technology highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Mallinckrodt PLC (MNK)
by Kevin Cook
Generic drug makers are one of the worst performing industries this year and there's little sign of a turnaround
Mallinckrodt (MNK) Tops Q2 Earnings, Misses on Sales
by Ekta Bagri
Mallinckrodt plc (MNK) beat earnings estimates in the second quarter but sales fell short due to weakness in generics segment.
Why Mallinckrodt (MNK) Might Surprise This Earnings Season
by Zacks Equity Research
Mallinckrodt (MNK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is Mallinckrodt (MNK) a Great Stock for Value Investors?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Mallinckrodt (MNK) Down 10% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
MNK reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Here's Why Mallinckrodt (MNK) Shares are Lower Today
by Madeleine Johnson
On Monday, shares of pharmaceutical company Mallinckrodt Plc. (MNK) are slipping, down about 5% to $40.50 per share in afternoon trading--MNK dropped about 8% in heavy morning trading--after a new report from short-seller Citron Research targeted the company.
Mallinckrodt (MNK) Tops Q1 Earnings, Sales
by Zacks Equity Research
Mallinckrodt beats on earnings and sales in the first quarter.
Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
by Zacks Equity Research
Mallinckrodt Public Limited Company (MNK) reported positive results for the transition quarter (Oct 1, to Dec 30, 2016) beating both sales and earnings expectations.
Mallinckrodt (MNK) Tops Earnings & Sales Estimates
by Ekta Bagri
Mallinckrodt beats both earnings and sales expectations in the transition quarter.
Bartosiak: Trading Mallinckrodt's (MNK) Earnings with Options
by David Bartosiak
Join Dave Bartosiak at 9:00am Central Time on Friday, February 3rd, to see his thoughts on Mallinckrodt (MNK) before they report earnings with real-time options insight.
Mallinckrodt to Sell Intrathecal Therapy Business for $203M
by Zacks Equity Research
Mallinckrodt plc (MNK), entered into an agreement to sell its Intrathecal Therapy business for approximately $203 million with Piramal.
Is Mallinckrodt (MNK) a Top Choice for Value Investors?
by Zacks Equity Research
Let's find out if Mallinckrodt Public Limited Company (MNK) stock is a good choice for value-oriented investors.
Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter
by Zacks Equity Research
Mallinckrodt plc (MNK), will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter???s investigation into the acquisition of Synacthen Depot by its Questcor division.
Research Reports for Amazon, IBM, Cisco & others
by Sheraz Mian
Today's must-read reports are for Amazon.com (AMZN), Visa (V) and Mallinckrodt (MNK).